SCHEMBL2447211

SCHEMBL2447211

[c]1nc2ccccc2cc1-c1cccc2cccnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
LMNA P02545 3/20 0.44
MMP2 P08253 2/20 0.44
TSHR P16473 2/20 0.44
CCR1 P32246 2/20 0.44
CCR5 P51681 2/20 0.44
CCR8 P51685 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
GMNN O75496 1/20 0.44
TP53 P04637 1/20 0.44
HSP90AA1 P07900 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
MMP9 P14780 1/20 0.44
ALOX15 P16050 1/20 0.44
NFKB1 P19838 1/20 0.44
MMP8 P22894 1/20 0.44
THPO P40225 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6770764 0.78 KMT2A (0.37) KDM4ELMNATSHRSMN1; SMN2TDP1
SCHEMBL2187375 0.78 KMT2A (0.42) KDM4ELMNATSHRSMN1; SMN2TDP1
SCHEMBL1385432 0.77 ALDH1A1 (0.42) KDM4ETSHRSMN1; SMN2TDP1TP53
SCHEMBL4722008 0.75 ALDH1A1 (0.39) KDM4ELMNATSHRSMN1; SMN2TP53
SCHEMBL2320187 0.74 KDM4E (0.47) KDM4ELMNATSHRCCR1CCR5
SCHEMBL9032374 0.74 CYP1A2 (0.49) KDM4ESMN1; SMN2TP53CYP3A4MAPT
SCHEMBL938744 0.73 ALDH1A1 (0.40) KDM4ECCR1CCR8TDP1MAPT
SCHEMBL15229223 0.73 ALDH1A1 (0.43) KDM4ETSHRSMN1; SMN2TP53HSP90AA1
SCHEMBL12853981 0.72 LMNA (0.68) KDM4ELMNAMMP2TSHRCCR1
SCHEMBL29377530 0.72 CYP2A6 (0.55) KDM4ELMNAMMP2TSHRCCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009003952-A2 COLUMN AND METHOD FOR PREPARING A BIOLOGICAL SAMPLE FOR PROTEIN PROFILING PRONOTA N.V. (BE) 2009-01-08 WO claimed
EP-3180003-B1 PKC-EPSILON INHIBITORS UNIV CALIFORNIA (US) 2022-01-12 EP disclosed
US-20210145838-A1 SELECTIVE PDE4D INHIBITORS AGAINST DEMYELINATING DISEASES UNIVERSITEIT MAASTRICHT (BE) 2021-05-20 US disclosed
EP-3773562-A1 SELECTIVE PDE4D INHIBITORS AGAINST DEMYELINATING DISEASES Universiteit Hasselt (BE) 2021-02-17 EP disclosed
US-10738002-B2 Halogenated benzotropolones as ATG4B inhibitors UNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE) 2020-08-11 US disclosed
WO-2019193091-A1 SELECTIVE PDE4D INHIBITORS AGAINST DEMYELINATING DISEASES UNIVERSITEIT HASSELT (BE) 2019-10-10 WO disclosed
EP-3544952-A1 HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS Universiteit Antwerpen (BE) 2019-10-02 EP disclosed
US-20190284130-A1 HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS UNIVERSITEIT ANTWERPEN (BE) 2019-09-19 US disclosed
WO-2018096088-A1 HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS UNIVERSITEIT ANTWERPEN (BE) 2018-05-31 WO disclosed
EP-3180003-A1 PKC-EPSILON INHIBITORS The Regents of the University of California (US) 2017-06-21 EP disclosed
EP-1907362-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen NV (BE) 2008-04-09 EP disclosed
EP-1907361-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen N.V. (BE) 2008-04-09 EP disclosed
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity DEVGEN NV (BE) 2008-02-14 US disclosed
WO-2007138112-A2 COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY DEVGEN N.V. (BE) 2007-12-06 WO disclosed
WO-2007138110-A2 COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY DEVGEN N.V. (BE) 2007-12-06 WO disclosed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP disclosed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO disclosed
WO-2007006547-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
WO-2007006546-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO disclosed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284130-A1 HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS ATG4B, ATG7, ATG4A KDM4E 962/4885LMNA 3856/4885MMP2 3645/4885
US-20080039442-A1 Compounds With Kv4 Ion Channel Activity KCNA4, HCN4, KCNN4 KDM4E 618/4885LMNA 904/4885MMP2 2373/4885
US-20210145838-A1 SELECTIVE PDE4D INHIBITORS AGAINST DEMYELINATING DISEASES PDE4A, PDE4D, PDE4B KDM4E 290/4885LMNA 3077/4885MMP2 1484/4885
US-10738002-B2 Halogenated benzotropolones as ATG4B inhibitors ATG4B, ATG7, BECN1 KDM4E 1039/4885LMNA 3483/4885MMP2 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.